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IFN-a is widely used in the therapy of melanoma (Agarwala and
Kirkwood, 1997; Grob et al, 1998). Although in subgroups of
patients this treatment is of clear clinical efficacy, in others no
obvious beneficial effects are observed. No clinical, immuno-
logical or molecular features predicting treatment’s outcomes
have been identified so far (Kirkwood, 1998). 
IFN-a administration can be associated with severe toxicity,
including gastrointestinal disorders, hypo- or hypertension, tachy-
cardia, fatigue/asthenia or headache, limiting clinical applications
(Vial and Descotes, 1994; Kirkwood, 1998). This wide spectrum
of effects suggests pleiotropic functions of IFN-a, consistent with
an extended number of target genes. 
Clearly, these side effects represent a major limitation to the
application of IFN-a therapy, particularly in the light of its unpre-
dictable results. 
A central element of modern pharmacogenomics is the identifi-
cation of surrogate markers for drug efficacy using multiparallel
approaches. The availability of tumour cell lines sensitive or resis-
tant to well defined effects of IFN-a provides tools to search 
for genes whose expression is restricted to either cell type in the
absence of cytokine exposure possibly leading to the development
of diagnostic reagents such as antibodies or enzyme assays. 
In this work we have used high-density oligonucleotide arrays
(Lipshutz et al, 1999; Rogge et al, 2000) to analyse the expression
pattern of about 7000 genes in RNA samples from melanoma cell
lines sensitive or resistant to IFN-a induced inhibition of prolifer-
ation and HLA class I induction. Furthermore, by applying the
same technology, we have evaluated the gene expression profiles
induced by IFN-a in cells sensitive or resistant to these discrete
effects. 
We report here on the identification of peculiar patterns of
genes, of potential diagnostic relevance, preferentially expressed
in either IFN-a-sensitive or -resistant melanoma cell lines. In
addition, we have characterized clusters of genes whose expres-
sion can be significantly modulated by IFN-a treatment of cells,
irrespective of their sensitivity to IFN-a induced inhibition of
proliferation and HLA class I upregulation. 
MATERIALS AND METHODS 
Cell lines and culture conditions 
ME15, ME51, ME59 and ME67 cell lines were generated in our
laboratory upon culture of cell suspensions derived from surgi-
cally excised melanoma metastases (Lüscher et al, 1994). A375
cell line was a gift from Dr Eberle (Basel, Switzerland) where
as D10 cell line was provided by Dr Rimoldi (Lausanne,
Switzerland). All cell lines were cultured in RPMI medium
supplemented with 10% FCS, glutamine (2 mM), sodium pyruvate
(1 mM), non-essential aminoacids, antibiotics and HEPES buffer
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(10 mM) (all from GIBCO Life Sciences, Paisley, UK). When
confluent, the cells were passaged by trypsinization. 
Proliferation assays 
Cell proliferation was evaluated upon culture of 5000 cells per
well in flat bottom 96 wells plates (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) in the presence or absence of the indi-
cated concentrations of IFN-a2a (Hoffmann-LaRoche, Basel,
Switzerland) over a 5 day period. De novo DNA synthesis was
measured by 3H-thymidine incorporation following overnight
incubation in the presence of the tracer, according to standard
methods. 
HLA class I expression 
Surface expression of HLA class I was monitored by flow-
cytometry, using a FITC-labelled mAb specific for a monomor-
phic determinant of HLA-A-B-C heavy chain or control, isotype
matched reagents (Pharmingen, San Diego, CA, USA), in cells
cultured for 48 hours in the presence or absence of IFN-a. Mean
fluorescence intensity (MFI) of stained cells was quantitatively
analysed. 
Detection of IFN-a a receptor mRNA by RT-PCR 
Double stranded cDNA used for the microarray experiments (lines
ME15, A375, ME51, ME59, ME67 and D10, see below) was used
as template for the amplification of a 370 base pair fragment of the
IFNAR2 receptor (Genbank: L42243) (Lutfalla et al, 1995).
Amplification was carried out using a commercial kit (Roche
Molecular Biochemicals; Cat-Nr.1 939 823) and the oligonucleo-
tides 5¢-TCA TAA GGA TGA GGC TGT GAG GAG-3¢ (NT
10–34) and 5¢-TGT CCA GTG TCT TGG GTA ATG CAC-3¢ (NT
380–366) following the manufacturers’ instructions. Samples
from 25 cycles PCR were subjected to agarose electrophoresis and
photographed under UV transillumination. 
Oligonucleotide array analysis 
Cultured melanoma cells were harvested by scraping and total
cellular RNA was extracted (Mahadevappa and Warrington, 1999;
Rogge et al, 2000). 10 mg from each sample were reverse
transcribed, labelled and processed by using a commercial kit
(Affymetrix, Santa Clara, CA) according to the supplier’s instruc-
tions (Fambrough et al, 1999). Upon alkaline heat fragmentation,
cDNA were hybridized to the arrays following standard proce-
dures as supplied with the microchips (Affymetrix, Santa Clara,
CA). Raw data were collected with a confocal laser scanner
(Hewlett Packard, Palo Alto, CA) and pixel levels were analysed
using a commercial software (GeneChip v3.1, Affymetrix, Santa
Clara, CA). Expression levels for each gene were calculated as
normalized average difference (nAD) of fluorescence intensity
as compared to hybridization to mismatched oligonucleotides,
expressed in arbitrary units. Figure 1 shows examples of genes
scoring positive or negative in different cell lines as detectable
on the chip unit. On average, >25% of the genes under investiga-
tion were positive in the cell lines tested. 
A threshold of 20 nAD units was assigned to any gene with a
calculated expression level lower than 20, since mRNA levels in
this low range could not be reliably assessed. Array to array
variations did not exceed 2% based on the hybridization of one
sample to 5 arrays from the same batch in a pilot study (Certa and
Neeb unpublished). In specific experiments (see below), change
factors (CF) of fluorescence levels, expressed as nAD units,
related to IFN-a exposure were also calculated. In order to
exclude artifacts, only genes with robust change factors, greater
than 3-fold, were included in the analysis. By applying these
criteria, about 50–70 genes were found to be modulated depending
on the cell lines under investigation. Genes were clustered according
to their mode of regulation (up = upregulated; dn = downregulated;
~ = unmodulated). 
Table 1 Effects of IFN-a on established melanoma cell lines 
Cell line Proliferation inhibition (IC50)a HLA class I inductionb
A375 + (100 U ml–1) (442 vs. 305) 
D10 –  (184 vs. 196) 
ME15 + (100 U ml–1) (521 vs. 257) 
ME51 + (10 U ml–1) (980 vs. 135) 
ME59 + (10 U ml–1) (559 vs. 380) 
ME67 –  (175 vs. 203) 
aMelanoma cell lines were cultured in the presence of IFN-a concentrations
ranging between 1 and 1000 U ml–1. 3H-thymidine incorporation was
measured daily over a 5 day culture period following an 18 hour pulsing time.
IC50 is the IFN-a concentration inducing at least a 50% inhibition of the
maximal proliferative activity detectable in individual experiments. 
bMelanoma cells were stained with HLA class I specific monomorphic mAbs
following a 2 day culture in the presence (left digits) or absence (right digits)
of IFN-a (100 U ml–1) and tested by flow-cytometry. Data are expressed as
mean fluorescence intensity of labelled cells. 
D10
6-16 jun
15/17kDa
ME15
Figure 1 Detection of gene expression by high density oligonucleotide
arrays. ME15 and D10 cells were cultured for 48 hours in the presence of
IFN-a (100 U ml–1). RNA was then extracted, reverse transcribed and
hybridized to high-density oligonucleotide arrays as described in the text.
Positive gene expression is detectable as fluorescent signal upon cDNA
hybridization on series of overlapping oligonucleotides aligned in adjacent
areas. The figure reports the detection of the expression of genes encoding
15/17 kDa (upper panels) and 6–16 jun (lower panels) in ME15 but not in
D10 cells (white frames). In contrast, house-keeping genes encoding
ribosomal protein L39 (upper panels, Genbank no. D79205) and lactate
dehydrogenase (lower panels, Genbank no. X02152) appear to be expressed
in both samples (black frames) IFN-a responsiveness in melanoma cells 109
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RESULTS 
Identification of IFN-a a sensitive and insensitive
melanoma cell lines 
A number of established melanoma cell lines were assayed for
their sensitivity to IFN-a by testing the capacity of this cytokine to
inhibit their proliferation and to increase their surface expression
of HLA class I determinants. 2 cell lines (D10 and ME67) were
found to be insensitive to the antiproliferative effects of IFN-a.
Proliferation of ME 51 and ME59 could be at least 50% inhibited by
IFN-a concentrations as low as 10 U ml–1, whereas A375 
and ME15 required a 10 times higher dose for the elicitations of
similar effects (Table 1). The upregulation of HLA class I expression
by IFN-a closely matched its antiproliferative effects and in no case
a dissociation of the 2 activities could be observed (Table 1). Figure 2
reports representative results related to D10 and ME15 cell lines. 
Experimental set up and detection of genes encoding
tumour-associated antigens in melanoma cell lines 
Total cellular RNA was extracted from the sensitive and resis-
tant melanoma cell lines characterized above, reverse tran-
scribed and processed for hybridization to an oligonucleotide
array (Hu6800FL, PN 900183, Affymetrix, Santa Clara, CA)
containing probe sets from full length human genes. 
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Figure 2 IFN-a induced inhibition of proliferation and HLA class I
upregulation in melanoma cell lines. ME15 (panels A and B) and D10
(panels C and D) melanoma cell lines were cultured in the presence (empty
histograms) or in the absence (shaded histograms) of IFN-a (100 U m–1) for
48 hours. Cells were then stained with a mAb recognizing a monomorphic
HLA-A-B-C determinant (panels B and D) or an isotype matched control
reagent (panels A and C). The proliferative capacity of the 2 cell lines (ME15,
panel E and D10, panel F) was also studied by 3H-thymidine incorporation
over a 5 days culture period in the absence of IFN-a or in the presence of
the indicated concentrations of the cytokine. Data are reported as cpm.
Standard deviations, never exceeding 10% of the reported values were
omitted 
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Figure 3 Panel A: Expression of genes encoding tumour-associated
antigens in melanoma cell lines. ME15, A375, ME51, ME59, ME67 and D10
cell lines were cultured for 48 hours in the presence (+) or absence (–) of 100
Um l –1 IFN-a. The expression patterns of genes encoding tyrosinase,
tyrosinase related protein-2, pmel-17 and mart-1 HLA restricted, tumour-
associated antigens are reported. Grey bars refer to IFN-a sensitive cell lines
and black bars refer to IFN-a resistant lines (see Table 1). Data are
presented as normalized average difference (nAD) of fluorescence intensity
between matched and mismatched oligonucleotide probe sets, expressed in
arbitrary units. Panel B: Detection of IFN-a receptor gene transcripts in
sensitive and resistant lines by 25 cycles RT-PCR. For any other detail see
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We first analysed data sets for genes encoding MART-1/Melan-
A, pmel-17 (gp100), TRP-2 and tyrosinase tumour-associated anti-
gens (TAA). In agreement with concomitantly performed
conventional and quantitative real time PCR assays (data not
shown), the 4 genes were found to be expressed in ME15 and D10
cell lines whereas virtually no expression was detectable in A375,
ME51, ME59 and ME67 cell lines (Figure 3A). These results were
consistent with our previously published data, showing that D10,
HLA-A2.1-positive, melanoma cells were effectively killed by
HLA-A2. 1-restricted CTL lines recognizing epitopes derived
from MART-1/Melan-A, pmel-17/gp 100, tyrosinase or TRP-2
proteins (Spagnoli et al, 1995; Noppen et al, 2000). In contrast,
ME59 HLA-A2.1 positive cells, that did not express the genes
under investigation failed to be killed by the specific CTL
(Spagnoli et al, 1995). Remarkably, IFN-a treatment did not appear
to influence the expression of the genes encoding these
TAA. 
Thus, the application of the microarray technology to the
cellular system under investigation was validated by results
obtained at functional and gene expression level. 
Transcripts from the IFN-a receptor gene (IFNAR2) were
detected at low levels (nAD ≤ 60; see also Table 2, gene cluster 5)
upon microarray hybridization of the cDNA from the cell lines
under investigation. To confirm and reinforce these data, however,
we evaluated IFN-a receptor gene expression by using a more
sensitive RT-PCR assay (Figure 3B). Although to different extents,
unrelated to the level of responsiveness to the cytokine, specific
transcripts could indeed be amplified from all lines. 
Detection of potential marker genes for IFN-a a
responsiveness 
The availability of large mRNA expression data sets from 6 human
melanoma cell lines well characterized for their responsiveness to
IFN-a raised the possibility of identifying genes preferentially
expressed in sensitive or resistant lines in the absence of cytokine
treatment. Microarray data of all genes from the responder (ME15,
ME51, ME59 and A375) and non-responder (D10, ME67) cells
were combined and screened for genes preferentially expressed in
either group. 
This analysis resulted in the identification of a group of 4 genes
prevailingly detectable in IFN-a sensitive cell lines (Figure 4,
panel A). 2 of them, IFI16 and RCC1 encode nuclear proteins
endowed with mitotic regulation and transcriptional activation
capacities, respectively (Bischoff and Ponstingl, 1991; Trapani 
et al, 1994). A third is the hox2 homeobox gene (Acampora et al,
1989), whereas the fourth, h19 gene, encodes an untranslated
RNA, involved in the DNA methylation and genetic imprinting
processes (Brannan et al, 1990). Notably, however, RCC1 gene
was not expressed in one IFN-a sensitive cell line (ME51). 
On the other hand, 2 genes encoding likely components of
signal transduction pathways, SHB and PKC-z (Barbee et al,
1993; Welsh et al, 1994) appeared to be preferentially expressed in
IFN-a resistant D10 and ME67 cell lines (Figure 4, panel B). 
Induction of gene expression by IFN-a a in sensitive and
resistant cell lines 
We then investigated the pattern of genes expressed in IFN-a-sensi-
tive and -insensitive melanoma cell lines upon culture in the pres-
ence of the cytokine. Since inhibitory effects on cell proliferation
were first detectable after 72 hour cultures (see Figure 1) we chose
to investigate gene expression in cells cultured for 48 hours in the
presence or absence of the cytokine. ME15 and D10 cell lines were
studied in detail. Our analysis focused on genes which were at least
3-fold up- or down-regulated as compared to untreated cells and
displayed nAD values of at least 50 in 1 of the 4 experiments. 
Table 2 reports data from 6 clusters of known IFN-a modulated
genes, previously found to be regulated by cytokine treatment in
one human fibrosarcoma cell line (Der et al, 1998). Indeed we
found that the expression of a number of them can also be modu-
lated by IFN-a in apparently resistant cells. Cluster 1 includes
genes only inducible in the sensitive ME15 cell line. As expected
the expression of these genes was not significantly affected by the
treatment in D10, IFN-a-resistant, cells. This set of genes includes
HLA class I genes, 2-5A synthetase, TAP-1, genes encoding a
number of interferon-inducible proteins, but also p27 cyclin-
dependent kinase inhibitor and ROX protein (Rasmussen et al,
1993; Nigro et al, 1998). A single gene, encoding amplaxin or
ems-1, and derived from a locus, 11q13, frequently amplified in
tumour cells (Shuurig, 1995) appears to be induced by IFN-a in
both lines (cluster 2). 
Cluster 3 genes, including ip-30, a known IFN-g inducible gene,
and dss 1 were induced in D10-resistant cell line but their expres-
sion was not significantly modified in ME15 sensitive cells.
Cluster 4 includes additional genes inducible by IFN-a in ME15
which are, in contrast to cluster 1, downregulated in IFN-a resis-
tant D10 cells. Remarkably, the transcription factor ISGF-3, of
relevance for IFN-a signalling belongs to this cluster that includes
other IFN-related genes. Cluster 5 comprises genes downregulated
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by IFN-a treatment in resistant D10 cells, but virtually unaffected
in sensitive ME15 cells. Interestingly, this cluster comprises the
gene encoding IFN-a receptor. Cluster 6 includes 2 genes (irf-2
and interferon-induced cellular resistance mediator) whose expres-
sion, basically undetectable in D10 resistant cell line, is downmod-
ulated in ME15 IFN-a sensitive cells. Notably, the IRF-2 gene
product is known to bind to the promoter region of IFN type I-
inducible genes and to prevent transcription (Itoh et al, 1989).
Downregulation could thus promote the activation of IFN
inducible genes. 
Detection of novel IFN-a a inducible genes 
Table 3 includes genes not previously described as IFN-a
inducible, whose expression was found to be upregulated upon
melanoma cells treatment. Cluster 1 comprises genes only induced
in sensitive cells, whereas cluster 2 refers to genes upregulated
upon IFN-a treatment of apparently insensitive melanoma cells.
Some of these genes obviously belong to melanocytic (melanoma
differentiation antigen, mda-6) or neuroectodermic (e.g.,
neuroleukin or catechol o-methyltransferase; Gurney et al, 1986;
Tenhunen et al, 1994) cell lineages, while other clearly inducible
genes such as those encoding, for instance, plasma gelsolin or
spermidine synthase escape an evident, similar, tissue-specific
classification. 
DISCUSSION 
IFN-a treatment is currently the only adjuvant therapy of proven
effectiveness in increasing disease-free interval and overall
survival in malignant melanoma, following potentially curative
surgery (Kirkwood, 1998). However, the administration of rela-
tively high doses of cytokine appears to be required (Agarwala and
Kirkwood, 1996; Grob et al, 1998; Keilholz and Eggermont,
2000), frequently resulting in severe toxic side effects, ranging
between flu-like symptoms, severe neuro-hepato-toxicity and
myelosuppression (Vial and Descotes, 1994). Clinical, immuno-
logical or molecular features enabling a targeted selection of
patients likely to take advantage of this therapy have not been
identified so far (Kirkwood, 1998). Only recently, baseline white
blood cell count has been suggested as a possible prognostic factor
of potential clinical relevance (de La Salmonière et al, 2000).
Clearly, the development of criteria predicting the potential effec-
tiveness of IFN-a therapy would be of high clinical relevance
since it would spare unnecessary toxicity to non-responders and it
would contribute to the identification of responders’ subgroups. 
In this work we addressed the genetic profile of melanoma cell
lines classified according to their sensitivity or insensitivity to crit-
ical direct effects of IFN-a, namely the inhibition of proliferation
and the upregulation of HLA class I expression. 
Oligonucleotide microarray technology allows us to investigate
the expression of large panels of genes and appears to be ideally
suited to the analysis of relatively simple cellular systems (Marton
et al, 1998; Iyer et al, 1999). In our hands its sensitivity was
confirmed by preliminary studies yielding results related to the
expression of melanoma-associated antigens consistent with those
obtained from functional assays or conventional PCR experi-
ments. 
Resistance to the antiproliferative and HLA class I-inducing
effects of IFN-a does not appear to be related to major differences
in the expression of genes encoding key players of the specific
signal transduction chain. STAT genes included in the array (2, 4,
5a and 5b) were found to be expressed at relatively low levels
(nAD ≤ 50) in all cell lines, irrespective of IFN-a responsiveness.
These results are in agreement with data obtained by using
different technologies, suggesting the presence of relatively func-
tional signal transduction in IFN-a insensitive cells (Ralph et al,
1995; Wong et al, 1997). Interestingly, similar results were also
obtained by testing some of the cell lines under investigation in the
current work by conventional gene and protein expression tech-
niques (Pansky et al, 2000). 
A pattern of genes preferentially expressed according to typical
profiles in sensitive and resistant cells clearly emerges. Genes
involved in the regulation of cell proliferation, such as IFI16, h19
and RCC1, but also hox2 (Acampora et al, 1989; Brannan et al,
1990; Bischoff and Ponstingl 1991; Trapani et al, 1994), were
found to be preferentially expressed in sensitive cell lines.
Intriguingly, genes encoding SHB and PKC-z proteins, known
components of defined signal transduction pathways (Barbee et al,
1993; Welsh et al, 1994), appear to be preferentially expressed 
in IFN-a resistant cells (Figure 4, panels A and B). These puzzling
data suggest that IFN-a resistance could result from a series 
of active events as opposed to a merely defective activation. 
IFN-a stimulation of sensitive melanoma cells resulted in the
detectable upregulation of a number of known inducible genes
(Table 2, cluster 1). For instance 6–16 and 27-sep genes, both
more than 20-fold upregulated in human fibrosarcoma cells (Der
et al, 1998) were found to be induced in ME 15 melanoma 54-and
102-fold respectively, while neither was detectable in the IFN-a
resistant line D10. Another classical interferon inducible gene,
2¢–5¢ oligosynthase, was upregulated in ME15 but not in D10
cells. These confirmatory results further validate the integrity of
the microarray analysis in this specific experimental framework.
Remarkably, the 27-sep gene product, the IFN inducible Leu-13
antigen, is implicated in growth control in several cell lines
(Deblandre et al, 1995). On the other hand the genes encoding
IFN-induced cellular resistance mediator protein (Aebi et al, 1989)
and IFN regulatory factor-2 (Schuurig, 1995) were clearly down-
regulated in the sensitive ME15 cell line (Table 2, cluster 6). 
Most interestingly, in cells apparently insensitive to the inhibi-
tion of proliferation and to the HLA class I induction determined
by IFN-a, a significant modulation of the expression of discrete
sets of genes could nevertheless be observed upon cytokine treat-
ment. The downregulation of a set of known interferon-related
genes, including those encoding the cytokine and its specific
receptor was matched by the upregulation of ip-30 and dss1 genes
(Luster et al, 1988; Crackower et al, 1996) (Table 2, cluster 3).
Clearly, these results are compatible with the hypothesis of
‘partial’ effects of IFN-a, upstream of inhibition of proliferation
and HLA class I induction. Importantly, these effects, on cells
conventionally classified as resistant, might also offer novel
insights into IFN-a related toxicity. 
A further important result is represented by the identification of
a group of 30 genes whose expression appears to be upregulated
by IFN-a treatment in melanoma cells (Table 3), but was not
reported in cells of different histological origin (Der et al, 1989).
Some of these genes are typically transcribed in neuroectodermic
tissues. It is tempting to speculate that their products might play a
role in exogenous IFN-a induced neurotoxicity (Adams et al,
1988) or that their upregulation by endogenously produced IFN-a
might be of relevance in defined neurological syndromes. Others,
however, including cytochrome c-1 gene, do not obviously pertain114 U Certa et al 
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to given tissue-specific transcription patterns. Further research is
warranted to clarify the role eventually played by the products of
these genes in discrete aspects of the polymorphic toxic effects of
IFN-a. 
Taken together our data provide an extended database of poten-
tial relevance in the investigation of the molecular background 
of IFN-a sensitivity of melanoma cells both, in clinical tumour
samples and in basic cell biology studies. Ongoing studies
addressing the validation of these data at the protein level might
result in the characterization of reagents of clinical interest. 
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